MedTrace Logo

Mobile Chat Messaging for Alcohol Reduction in Patients With Chronic Liver Diseases

NCT06587568 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2025-05-01

No results posted yet for this study

Summary

The goal of this pilot randomized controlled trial is to evaluate the trial feasibility and acceptability of mobile chat messaging for reducing alcohol use among patients with chronic liver diseases. Specific objectives include:

1. To assess whether the eligibility criteria were too restrictive by estimating the eligibility rate
2. To assess how many eligible CLD patients accepted the invitation to participate in the trial
3. To assess the participant retention rate through 6 months after treatment initiation
4. To assess the intervention acceptability in terms of participants' engagement with and rating of the chat messaging intervention.
5. To assess the safety of the intervention
6. To estimate the intervention effect on alcohol use outcomes and liver functions
7. To synthesise data to inform the sample size calculation in the future definitive trial
8. To explore the participants' perception and experiences in the chat-based intervention

Conditions

Interventions

BEHAVIORAL

Mobile chat messaging

A trained counsellor will interact with a participant individually and provide personalised alcohol reduction information and advice via a mobile instant messaging app in real time for 3 months from randomisation.

BEHAVIORAL

Screening, brief intervention and referral to treatment

Brief counselling (5 to 10 mins) to reduce drinking and a self-help booklet

Sponsors & Collaborators

  • Health and Medical Research Fund

    collaborator OTHER_GOV

  • The University of Hong Kong

    lead OTHER

Principal Investigators

  • Tzu Tsun Luk, PhD, RN · The University of Hong Kong

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-10-02
Primary Completion
2025-11-30
Completion
2025-12-31

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06587568 on ClinicalTrials.gov